Gotham Asset Management LLC Purchases 13,986 Shares of IDEXX Laboratories, Inc. $IDXX

Gotham Asset Management LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 40.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,643 shares of the company’s stock after purchasing an additional 13,986 shares during the period. Gotham Asset Management LLC owned 0.06% of IDEXX Laboratories worth $31,078,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC increased its holdings in IDEXX Laboratories by 2.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after purchasing an additional 15 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after acquiring an additional 16 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after acquiring an additional 17 shares in the last quarter. Private Trust Co. NA raised its holdings in shares of IDEXX Laboratories by 9.4% in the third quarter. Private Trust Co. NA now owns 209 shares of the company’s stock valued at $134,000 after purchasing an additional 18 shares during the last quarter. Finally, Ascent Group LLC raised its holdings in shares of IDEXX Laboratories by 2.9% in the third quarter. Ascent Group LLC now owns 632 shares of the company’s stock valued at $404,000 after purchasing an additional 18 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on IDXX. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. UBS Group dropped their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Wall Street Zen downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Trading Up 2.2%

Shares of IDEXX Laboratories stock opened at $586.37 on Tuesday. The stock has a market capitalization of $46.69 billion, a P/E ratio of 44.86, a P/E/G ratio of 3.48 and a beta of 1.66. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock’s 50-day simple moving average is $656.25 and its 200 day simple moving average is $666.45.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the business earned $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 2,693 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the sale, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. This represents a 11.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,957 shares of company stock worth $29,862,109 in the last 90 days. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.